Effect of high-dose oral N-acetylcysteine versus placebo on serum level of oxidative and nirtosative stress and clinical outcomes in patients with ischemic stroke

Effect of high-dose oral N-acetylcysteine versus placebo on serum level of oxidative and nirtosative stress and clinical outcomes in patients with ischemic stroke: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150629022965N16

Enrollment

Registered

2018-07-15

Start date

2018-07-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: routine stroke treatment plus oral N-acetylcysteine tablet 200 mg with 4 g loading dose,after 18-24 h 4g,every 12 hours 2g for 2 days. Intervention 2: Control grou

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age: 18 to 85 years old Ischemic stroke Stroke for the first time Local neurologic disorder Patients who have been admitted for the first 24 hours after the stroke

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Inflammatory disease Asthma History of anaphylaxis shock

Design outcomes

Primary

Measure	Time frame
Modified Rankin Scale for Neurologic Disability. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.;Serum level of lipid peroxidation. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of nitric oxide. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of total antioxidant capacity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Catalase activity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of superoxide dismutase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum level of thiol. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of Glutathione Peroxidase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;National Institutes of Health Stroke Scale. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.	—

Measure

Time frame

Modified Rankin Scale for Neurologic Disability. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.;Serum level of lipid peroxidation. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of nitric oxide. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of total antioxidant capacity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Catalase activity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of superoxide dismutase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum level of thiol. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of Glutathione Peroxidase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;National Institutes of Health Stroke Scale. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mehrpooya

Hamedan University of Medical Sciences

m_mehrpooya2003@yahoo.com+98 81 3838 0717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026